Boston Scientific's new stent may get priority reviewhttp://biz.yahoo.com/rc/030313/health_bostonscientific_taxus_1.htmlBoston Scientific Corp. (NYSE:BSX - News) said on Thursday its experimental device for preventing re-clogging of arteries would likely be reviewed more quickly than normal by U.S. regulators....Boston Scientific said the U.S. Food and Drug Administration (News - Websites) will review the company's Taxus stent before it reviews pending applications on other drugs and devices....Johnson & Johnson (NYSE:JNJ - News) is already marketing it drug-coated stent, called Cypher, in Europe and is awaiting U.S. approval.Boston Scientific has said it expects sales to jump to $5.4 billion in 2004 from a projected $3.4 billion in 2003 as its drug-coated stent becomes widely used. Taxus is already approved in Europe.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra